|
B-Cell Lymphomas
|
0.400 |
Biomarker
|
group |
BEFREE |
Mechanistically, EZH2 specifically stabilizes the chromatin accessibility of a cluster of genes that are important for T<sub>FH</sub> fate commitment, particularly B cell lymphoma 6 (Bcl6), and thus directs T<sub>FH</sub> cell commitment.
|
30842630 |
2020 |
|
B-Cell Lymphomas
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Follicular lymphoma (FL) is the most common indolent B-cell non-Hodgkin lymphoma (NHL) with genetic alterations of BCL-2, KMT2B, and KMT6.
|
30693983 |
2019 |
|
B-Cell Lymphomas
|
0.400 |
Biomarker
|
group |
BEFREE |
The effects of ribavirin on the viability and clonogenicity of the B‑cell lymphoma cell line Pfeiffer (EZH2‑mutant), Toledo (EZH2 wild‑type) and cutaneous T‑cell lymphoma Hut78 cell line were assessed.
|
31322273 |
2019 |
|
B-Cell Lymphomas
|
0.400 |
Biomarker
|
group |
BEFREE |
These drugs include immunomodulating agents such as lenalidomide, small-molecule inhibitors of the B-cell receptor signaling pathway such as ibrutinib and idelalisib, B-cell lymphoma 2 homology 3 mimetics such as venetoclax, and enhancer of zeste homolog 2 inhibitors such as tazemetostat.
|
31808854 |
2019 |
|
B-Cell Lymphomas
|
0.400 |
AlteredExpression
|
group |
BEFREE |
We studied EZH2 expression in nodular lymphocyte predominant Hodgkin lymphoma (NLPHL), classic Hodgkin lymphoma (cHL), T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL), and B-cell Lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphomas and classic Hodgkin lymphoma (BCLu-DLBCL/cHL), as well as the coexpression of p-ERK, MYC, and p-STAT3 in these neoplasms.
|
30371509 |
2019 |
|
B-Cell Lymphomas
|
0.400 |
Biomarker
|
group |
BEFREE |
Dysregulation of the histone methyltransferase EZH2 plays a critical role in the development of a variety of malignancies including B-cell lymphomas.
|
29473431 |
2018 |
|
B-Cell Lymphomas
|
0.400 |
GeneticVariation
|
group |
BEFREE |
A subset of B-cell lymphoma patients have dominant mutations in the histone H3 lysine 27 (H3K27) methyltransferase EZH2, which change it from a monomethylase to a trimethylase.
|
28556566 |
2017 |
|
B-Cell Lymphomas
|
0.400 |
Biomarker
|
group |
BEFREE |
These emerging data suggest that EZH2 inhibitors represent a very promising class of drugs, which will probably have a major impact on improving outcome and reducing toxicity for patients with indolent and aggressive B-cell lymphomas and other specific solid tumors.
|
27179746 |
2016 |
|
B-Cell Lymphomas
|
0.400 |
Biomarker
|
group |
BEFREE |
Pharmacological EZH2 inhibitors are currently in clinical trials for the treatment of B-cell lymphomas and solid tumors.
|
26411517 |
2016 |
|
B-Cell Lymphomas
|
0.400 |
Biomarker
|
group |
BEFREE |
Furthermore, EZH2 and associated signaling cascades may serve as therapeutic targets for the treatment of aggressive B-cell lymphomas.
|
27282353 |
2016 |
|
B-Cell Lymphomas
|
0.400 |
GeneticVariation
|
group |
BEFREE |
We discuss our current understanding of EZH2 somatic mutations frequently found in B-cell lymphomas and recurrent mutations in various other epigenetic regulators as novel molecular predictors and determinants of PRC2 sensitivity.
|
26027790 |
2015 |
|
B-Cell Lymphomas
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Immunoblot of DLBCL cell lines and microarray gene expression study of EZH2 in B-cell lymphomas were consistent with the immunohistochemistry findings.
|
25651430 |
2015 |
|
B-Cell Lymphomas
|
0.400 |
Biomarker
|
group |
BEFREE |
These findings represent a novel promising approach for silencing MYC-miRNA-EZH2 amplification loop for combinatorial therapy of aggressive B-cell lymphomas.
|
23538750 |
2013 |
|
B-Cell Lymphomas
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The Ki67 labeling index showed a positive correlation with Ezh2 expression in B cell lymphomas (correlation coefficient (Co) = 0.983, P = 0.000) and T/NK cell lymphomas (Co = 0.629, P = 0.000).
|
23948956 |
2013 |
|
B-Cell Lymphomas
|
0.400 |
AlteredExpression
|
group |
BEFREE |
We were also able to link these distinct microRNA profiles with cellular phenotypes, importantly showing that, in subset 1, miR-101 downregulation is associated with overexpression of the enhancer of zeste homolog 2 (EZH2) protein, which has been associated with clinical aggressiveness in other B-cell lymphomas.
|
23615967 |
2013 |
|
B-Cell Lymphomas
|
0.400 |
Biomarker
|
group |
BEFREE |
Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27).
|
22323599 |
2012 |
|
B-Cell Lymphomas
|
0.400 |
Biomarker
|
group |
BEFREE |
Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas.
|
23079660 |
2012 |
|
B-Cell Lymphomas
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Our findings suggest that EZH2 mutations constitute an additional genetic "hit" in many BCL2-rearranged germinal center B cell lymphomas.
|
22194861 |
2011 |
|
B-Cell Lymphomas
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Point mutations of the EZH2 gene (Tyr641) have been reported to be linked to subsets of human B-cell lymphoma.
|
21078963 |
2010 |
|
B-Cell Lymphomas
|
0.400 |
CausalMutation
|
group |
CGI |
|
|
|